Human Growth Hormone Injection Market Size Expected to Reach USD 8.54 Bn by 2035

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Recombinant DNA (rDNA) HGH segment was dominant in the market revenue in 2024, with an 85% share

  80% confidence

• In-house manufacturing segment was dominant in the human growth hormone injection market in 2024, with a 70% share

  80% confidence

• The global human growth hormone injection market size is calculated at USD 4.82 billion in 2026 and is expected to reach around USD 8.54 billion by 2035, growing at a CAGR of 6.55%

  80% confidence

• Novo Nordisk spent nearly $6.3 billion last year to bolster its manufacturing capabilities

  80% confidence

• Branded HGH injections segment held the largest market revenue of 65% in 2024

  80% confidence

• Generic HGH injections segment is the fastest-growing over the forecast period, 2025 to 2034

  80% confidence

• Novo Nordisk spent approximately $9 billion in 2025 to create additional capacity across the supply chain

  80% confidence

• Metabolic disorders segment is expected to register the fastest growth over the forecast period, 2025 to 2034

  80% confidence

• Subcutaneous injection segment was dominant in the market in 2024, with a 90% share

  80% confidence

• Pediatric growth disorders segment was dominant in the human growth hormone injection market in 2024, with a 40% share

  80% confidence

• Asia Pacific is expected to be the fastest-growing region over the forecast period, 2025 to 2034

  80% confidence

• Hospital pharmacies segment was dominant in the market in 2024, with a 45% share

  80% confidence

• Online pharmacies segment is expected to register the fastest growth over the forecast period, 2025 to 2034

  80% confidence

• North America was dominant in the human growth hormone injection Market, with a 55% share

  80% confidence

• Pfizer's Somatropin-LA shows promising Phase 3 results for pediatric growth hormone deficiency with improved weekly dosing benefits

  80% confidence

• Outsourced manufacturing segment is expected to register the fastest growth over the forecast period, 2025 to 2034

  80% confidence

Data points we hold from this source